Literature DB >> 28344883

Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity.

Stéphane Terry1, Stéphanie Buart1, Tuan Zea Tan2, Gwendoline Gros1, Muhammad Zaeem Noman3, James B Lorens4, Fathia Mami-Chouaib1, Jean Paul Thiery5, Salem Chouaib1.   

Abstract

Tumor escape to immunosurveillance and resistance to immune attacks present a major hurdle in cancer therapy, especially in the current era of new cancer immunotherapies. We report here that hypoxia, a hallmark of most solid tumors, orchestrates carcinoma cell heterogeneity through the induction of phenotypic diversity and the acquisition of distinct epithelial-mesenchymal transition (EMT) states. Using lung adenocarcinoma cells derived from a non-metastatic patient, we demonstrated that hypoxic stress induced phenotypic diversity along the EMT spectrum, with induction of EMT transcription factors (EMT-TFs) SNAI1, SNAI2, TWIST1, and ZEB2 in a hypoxia-inducible factor-1α (HIF1A)-dependent or -independent manner. Analysis of hypoxia-exposed tumor subclones, with pronounced epithelial or mesenchymal phenotypes, revealed that mesenchymal subclones exhibited an increased propensity to resist cytotoxic T lymphocytes (CTL), and natural killer (NK) cell-mediated lysis by a mechanism involving defective immune synapse signaling. Additionally, targeting EMT-TFs, or inhibition of TGF-β signaling, attenuated mesenchymal subclone susceptibility to immune attack. Together, these findings uncover hypoxia-induced EMT and heterogeneity as a novel driving escape mechanism to lymphocyte-mediated cytotoxicity, with the potential to provide new therapeutic opportunities for cancer patients.

Entities:  

Keywords:  EMT; Antitumor cytotoxic response; CTL; HIF; NK cells; NSCLC; TGF-β; hypoxia

Year:  2017        PMID: 28344883      PMCID: PMC5353930          DOI: 10.1080/2162402X.2016.1271858

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  32 in total

1.  Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.

Authors:  Yanyan Lou; Lixia Diao; Edwin Roger Parra Cuentas; Warren L Denning; Limo Chen; You Hong Fan; Lauren A Byers; Jing Wang; Vassiliki A Papadimitrakopoulou; Carmen Behrens; Jaime Canales Rodriguez; Patrick Hwu; Ignacio I Wistuba; John V Heymach; Don L Gibbons
Journal:  Clin Cancer Res       Date:  2016-02-05       Impact factor: 12.531

2.  In situ sensory adaptation of tumor-infiltrating T lymphocytes to peptide-MHC levels elicits strong antitumor reactivity.

Authors:  Guillaume Dorothée; Isabelle Vergnon; Faten El Hage; Béatrice Le Maux Chansac; Vincent Ferrand; Yann Lécluse; Paule Opolon; Salem Chouaib; Georges Bismuth; Fathia Mami-Chouaib
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

3.  Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis.

Authors:  Intissar Akalay; Bassam Janji; Meriem Hasmim; Muhammad Zaeem Noman; Fabrice André; Patricia De Cremoux; Philippe Bertheau; Cécile Badoual; Philippe Vielh; Annette K Larsen; Michèle Sabbah; Tuan Zea Tan; Joan Herr Keira; Nicole Tsang Ying Hung; Jean Paul Thiery; Fathia Mami-Chouaib; Salem Chouaib
Journal:  Cancer Res       Date:  2013-02-22       Impact factor: 12.701

Review 4.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

5.  A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.

Authors:  Milena P Mak; Pan Tong; Lixia Diao; Robert J Cardnell; Don L Gibbons; William N William; Ferdinandos Skoulidis; Edwin R Parra; Jaime Rodriguez-Canales; Ignacio I Wistuba; John V Heymach; John N Weinstein; Kevin R Coombes; Jing Wang; Lauren Averett Byers
Journal:  Clin Cancer Res       Date:  2015-09-29       Impact factor: 12.531

6.  Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.

Authors:  G Maki; H G Klingemann; J A Martinson; Y K Tam
Journal:  J Hematother Stem Cell Res       Date:  2001-06

7.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.

Authors:  Chie Kudo-Saito; Hiromi Shirako; Tadashi Takeuchi; Yutaka Kawakami
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis.

Authors:  Audrey Le Floc'h; Abdelali Jalil; Isabelle Vergnon; Béatrice Le Maux Chansac; Vladimir Lazar; Georges Bismuth; Salem Chouaib; Fathia Mami-Chouaib
Journal:  J Exp Med       Date:  2007-02-26       Impact factor: 14.307

9.  Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy.

Authors:  Bee Luan Khoo; Soo Chin Lee; Prashant Kumar; Tuan Zea Tan; Majid Ebrahimi Warkiani; Samuel G W Ow; Sayantani Nandi; Chwee Teck Lim; Jean Paul Thiery
Journal:  Oncotarget       Date:  2015-06-20

10.  Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation.

Authors:  Carmen Chak-Lui Wong; Daniele M Gilkes; Huafeng Zhang; Jasper Chen; Hong Wei; Pallavi Chaturvedi; Stephanie I Fraley; Chun-Ming Wong; Ui-Soon Khoo; Irene Oi-Lin Ng; Denis Wirtz; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-12       Impact factor: 11.205

View more
  27 in total

1.  Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers.

Authors:  Ian MacFawn; Hannah Wilson; Luke A Selth; Ian Leighton; Ilya Serebriiskii; R Christopher Bleackley; Osama Elzamzamy; Joshua Farris; Phillip M Pifer; Jennifer Richer; Steven M Frisch
Journal:  Mol Immunol       Date:  2018-11-30       Impact factor: 4.407

Review 2.  Tumor Plasticity and Resistance to Immunotherapy.

Authors:  Lucas A Horn; Kristen Fousek; Claudia Palena
Journal:  Trends Cancer       Date:  2020-03-04

Review 3.  Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.

Authors:  John D Martin; Horacio Cabral; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2020-02-07       Impact factor: 66.675

Review 4.  Epithelial-Mesenchymal Plasticity in Tumor Immune Evasion.

Authors:  Riley D Z Mullins; Ananya Pal; Thomas F Barrett; Molly E Heft Neal; Sidharth V Puram
Journal:  Cancer Res       Date:  2022-07-05       Impact factor: 13.312

Review 5.  Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression.

Authors:  Kaumudi Bhawe; Deodutta Roy
Journal:  Cell Oncol (Dordr)       Date:  2018-07-25       Impact factor: 6.730

Review 6.  Non-redundant functions of EMT transcription factors.

Authors:  Marc P Stemmler; Rebecca L Eccles; Simone Brabletz; Thomas Brabletz
Journal:  Nat Cell Biol       Date:  2019-01-02       Impact factor: 28.824

Review 7.  Mesenchymal-epithelial transition in development and reprogramming.

Authors:  Duanqing Pei; Xiaodong Shu; Ama Gassama-Diagne; Jean Paul Thiery
Journal:  Nat Cell Biol       Date:  2019-01-02       Impact factor: 28.824

Review 8.  Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity.

Authors:  Stéphane Terry; Stéphanie Buart; Salem Chouaib
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

Review 9.  Deciphering Epithelial-Mesenchymal Transition Regulatory Networks in Cancer through Computational Approaches.

Authors:  Gerhard A Burger; Erik H J Danen; Joost B Beltman
Journal:  Front Oncol       Date:  2017-08-03       Impact factor: 6.244

Review 10.  New insights into the role of EMT in tumor immune escape.

Authors:  Stéphane Terry; Pierre Savagner; Sandra Ortiz-Cuaran; Linda Mahjoubi; Pierre Saintigny; Jean-Paul Thiery; Salem Chouaib
Journal:  Mol Oncol       Date:  2017-06-27       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.